Clinical Trials Logo

Drug Hypersensitivity clinical trials

View clinical trials related to Drug Hypersensitivity.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06303128 Recruiting - Penicillin Allergy Clinical Trials

Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge

Start date: February 3, 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to learn about dosing when testing to see if a penicillin allergy label can be removed from adults that had been labeled as "penicillin-allergic" previously. The main question it aims to answer is: - In penicillin-allergic patients that are at low risk of having an allergic reaction, is a one-dose oral challenge with amoxicillin (a penicillin-based antibiotic) as safe and effective as a two-dose oral challenge? Participants will, after being identified as having a low-risk penicillin allergy, be administered oral amoxicillin in a controlled setting and then monitored for an allergic reaction. Researchers will compare participants that took one dose of amoxicillin to participants that took two doses of amoxicillin (a small dose and then a larger dose) to see if either group was more likely to develop an allergic reaction.

NCT ID: NCT06112470 Recruiting - Allergy Penicillin Clinical Trials

Alleged Drug Allergies in Military General Medicine: Patients' Experiences and Beliefs

ALLMED
Start date: February 28, 2023
Phase:
Study type: Observational

This study focuses on the experience of the military patient reporting a suspected drug allergy, with its own specificities. Suspicions of drug allergies during a mission expose the doctor to difficulties. This study will improve understanding of the allergy patient's point of view. The end result could be a set of ideas for measures to raise awareness among these patients, and motivate them to undergo an allergological assessment.

NCT ID: NCT06067919 Recruiting - Clinical trials for Good Comprehension of French Language

Assessment of the Applicability and Acceptability of an Algorithm to Guide the Prescription of 1st and 2nd Generation Cephalosporins as Part of Intraoperative Antibiotic Prophylaxis in Patients With a Declared Allergy to Penicillin

PROPHYLAL
Start date: October 9, 2023
Phase: N/A
Study type: Interventional

According to the Centers for Disease Control and Prevention (CDC), a surgical site infection (SSI) is an infection that occurs after surgery at the site where the surgery was performed. The prevalence of SSIs is difficult to obtain and is probably underestimated, as many SSIs occur after the patient has been discharged from hospital and are not taken into account. SSIs are responsible for an increase in length of stay, mortality and costs. Their prevention is therefore essential in the operating theater, and has been the subject of recommendations recently updated by the CDC. The first line of prevention is the administration of prophylaxis antibiotic adapted to the surgical procedure, administered within a specific timeframe in order to achieve an effective bactericidal concentration in the tissues at the time of the surgical incision. In France, in the United States and for the WHO, the recommended first line of antibiotic prophylaxis is most often an agent from the beta-lactam family, a penicillin or a cephalosporin, with the exception of ophthalmological surgery. No strategy is described for the management of patients with a reported allergy to penicillin, apart from the recommendation of therapeutic alternatives. The use of a decision-making strategy in the operating theater for patients with a reported allergy to penicillin therefore appears necessary and is recommended by experts. In the intraoperative context, the application of a strategy would make it possible to guide the use of cephalosporins, without removing the "penicillin allergy" label from the patient, but by proposing an alternative via the use of a cephalosporin depending on the probability of the risk of a real allergy to penicillin, according to the description of the former reaction.

NCT ID: NCT06065137 Recruiting - Hypersensitivity Clinical Trials

Standardised Drug Provocation Testing in Perioperative Hypersensitivity

Start date: October 23, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and outcome of systematic drug provocation testing with anaesthetics at therapeutic doses in adult patients undergoing diagnostic work-up for perioperative hypersensitivity.

NCT ID: NCT05823155 Recruiting - Penicillin Allergy Clinical Trials

Impact of Pre-operative Penicillin Allergy Evaluation on Surgical Prophylaxis

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Use of first-line pre-operative antibiotic prophylaxis is the most effective measure to optimize perioperative outcomes. However, this is often not achieved due to unsubstantiated penicillin allergy labels. Penicillin allergy evaluation, when incorporated into routine pre-operative assessment, is potentially effective in optimizing choice of surgical prophylaxis. Despite the encouraging data mentioned above, there is a lack of randomized trials or local data to support this practice.

NCT ID: NCT05820802 Recruiting - Clinical trials for Neuromuscular Blockade

High Dimensional Analysis of Immune Cells in Pediatric Patients

Start date: April 27, 2023
Phase:
Study type: Observational

The purpose of this study is to characterize immune cells using single-cell transcriptomic analysis in pediatric patients aged 2 to 18 years undergoing general anesthesia who are expected to receive Rocuronium, a non-depolarizing neuromuscular blocking agent, in the event of an allergic reaction.

NCT ID: NCT04920721 Recruiting - Drug Allergy Clinical Trials

Retrospective Study of Immediate Hypersensitivity (IHS) Reactions to Platinum Salts in the University Hospital of Nancy

Start date: June 2021
Phase:
Study type: Observational

To assess the efficacy of skin tests with platinum salts in patients suspects with immediate hypersensitivity reactions. All patients adressed in consultation to the Allergy Department of university hospital of nancy for an immediate hypersensitivity reaction to platinum salts between 2015 and 2021 were retrospectively recruited.

NCT ID: NCT04654923 Recruiting - Clinical trials for Hypersensitivity, Drug

GERAP's Epidemiological Survey on Perioperative Hypersensitivity Reactions

SERAP
Start date: November 12, 2020
Phase:
Study type: Observational

Perioperative hypersensitivity reactions are still associated with significant morbidity and mortality despite early recognition and use of epinephrine. The epidemiology of these reactions evolves over time and changes with clinical practice. The main objective is to study the epidemiology of these reactions over a 10-year period, including patient phenotype, reaction phenotype and outcome of the allergic work-up.

NCT ID: NCT04610242 Recruiting - Clinical trials for Drug Hypersensitivity Reaction

Prediction of Rituximab Hypersensitivity and Desensitization Treatment

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

This is a single-center prospective single arm study. The purpose of this study is to assess the usefulness of skin test as a diagnostic tool to predict the hypersensitivity to rituximab in Chinese population, evaluate the rate of hypersensitivity reactions (HSRs) after the application of active desensitization therapy in the case of a positive skin test result, and investigate the mechanism of HSRs to rituximab.

NCT ID: NCT04330118 Recruiting - Clinical trials for Drug Hypersensitivity

Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome

DRESSEO
Start date: July 15, 2020
Phase:
Study type: Observational

Drug Hypersensitivity Syndrome or DRESS for "Drug Reaction with Eosinophilia and Systemic Symptoms" is a serious drug allergy which can be life-threatening for patients with serious organ damage. The pathophysiology of DRESS is still not fully understood. In particular, no study has focused on the characterization of eosinophils, while paradoxically eosinophilia is one of the diagnostic criteria. Likewise, there is no data about the origin of eosinophils and few data are available concerning immune polarization of T-cells or the involvement of innate lymphoid cells type 2 in the recruitment of eosinophils. Our preliminary data on increase activation markers membrane expression of cutaneous eosinophils suggest that this approach could allow the identification of endotypes in which eosinophils are involved and contribute to organ damages. The correlation between tissue infiltration of eosinophils and their degree of activation would then justify the development of targeted therapeutic strategies in DRESS syndrome (anti-IL-5 therapy?). The aim of the project is: 1) Evaluate the activation status of circulating and cutaneous eosinophils in patients with DRESS compared with drug induced maculopapular exanthema without or with eosinophilia (but do not fulfill DRESS criteria) and healthy subjects; 2) Understand the pathophysiological mechanisms at the origin of this eosinophilia.